Research
At the Clinical Neuroinformatics & AI Laboratory (CNAIL), we are transforming health care through research that bridges neuroscience, bioinformatics, and artificial intelligence. We develop cutting-edge tools and AI-driven algorithms to uncover clinical biomarkers, improve diagnostics, and enhance monitoring for neurological and neurodevelopmental conditions.
What is our vision?
- Harness AI to revolutionize healthcare delivery and diagnostic accuracy.
- Identify biomarkers that enable early intervention and personalized treatments.
- Extend healthcare innovations to underserved communities through global partnerships.
What do we research?
Our research spans a wide range of conditions, including autism, epilepsy, anxiety, and Alzheimer’s disease.
Very early autism detection
This research is done in collaboration with Harvard Medical School, Boston Children’s Hospital, the University of Texas at San Antonio, and the NY Institute for Basic Research on Developmental Disorders. A private startup, mHealthcare, Inc, is seeking funding to partner with us for clinical testing of this technology. USF Nursing students are organizing laboratory testing to develop clinical protocols for our novel approach to monitoring infant brain development.
Early detection and monitoring of childhood anxiety and depression
Led by child psychologist Michelle Bosquet Enlow at Harvard Medical School, Dr. Bosl serves as the principal neuroscientist on a project aimed at identifying brain-based biomarkers for these prevalent disorders.
Epilepsy
Detection of childhood epilepsies and personalized therapeutic plans based on personalized EEG analysis is being sought with the Epilepsy Center at Boston Children’s Hospital.
Sleep disorders and nocturnal epilepsy
In collaboration with the Sleep Clinic and Epilepsy Center at Boston Children’s Hospital, our research endeavors extend to identifying biomarkers for nocturnal epileptiform discharges linked to autism, investigating atypical sleep architectures associated with diverse disorders, and exploring cognitive impairment resulting from sleep disorders. Professor Bosl, along with Boston Children’s Hospital, holds a patent for epilepsy and epileptogenicity biomarkers, which is available for licensing.
PTSD therapy
Funding is being sought for a partnership with Trident.ai and the iHealth Lab to develop clinical biomarkers for PTSD and for monitoring therapeutic effectiveness, based on Professor Bosl’s algorithms for analyzing EEG signals.
Early detection of Alzheimer’s disease and acoustic intervention
This research was initiated after our faculty gave a presentation to the Indonesian Alzheimer’s Association on new technologies for Alzheimer’s. A new startup, Trident.ai, is working with us to seek private funding to support our faculty to pursue clinical research to demonstrate that early biomarkers that detect aberrations in brain function, are possible years before symptoms of mild cognitive impairment appear.
Global mental health
We are working closely with partners with the Global Organization of Health Education and PurplePoint Neurodiagnostics to take our innovations to low income and low resource regions of the world. In addition, we are developing curricula to increase research capacity in the countries where we work.